Pemphigus foliaceus: an adverse reaction to lisinopril

Patterson, Clare; Davies, Morton R.

doi:10.1080/09546630310013379

Cited by 24 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, given the temporal association between the patient's isolated Lisinopril dose escalation and her skin eruptions 2 months later, a drug‐induced adverse reaction was entertained. Particularly, drug‐induced pemphigus foliaceus (PF), another autoimmune blistering skin disorder, was highly suspected, given its previous reporting twice within the literature in association with Lisinopril use , along with the flaccid, eroded and crusted nature of our patient's skin lesions and their mucous‐sparing distribution .…”

Section: Case Presentationmentioning

confidence: 89%

Lisinopril‐associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction

Ballout

Musharrafıeh

Khattar

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

An 87-year-old woman with a long-standing history of hypertension, hypothyroidism and diabetes presented to us with scaly and pruritic vesicles of an erythematous base and crusted surface of 2-month duration. They first appeared on her abdomen and gradually spread to her lower back, thighs, before spreading to her upper and lower limbs. Her lesions were non-painful, aggravated by sun exposure only, and sparing mucous membranes. Nikolsky sign was positive with no discernible fluid-filled bullae. History was remarkable only for a doubling of her Lisinopril dosage 2 months prior to the appearance of her lesions, with no other potential environmental and/or drug triggers recognizable on history taking. In light of the appearance of her lesions after her Lisinopril dose escalation, in the absence of any other discernible triggers, an adverse drug reaction (ADR) was entertained, yielding a corresponding Naranjo ADR probability score of 7. Particularly, drug-induced pemphigus foliaceus was initially suspected given her clinical presentation and the morphology and distribution of her lesions. However, her skin biopsy altered our diagnosis to drug-induced bullous pemphigoid (BP) instead, making this the second case reported to date on Lisinopril-induced BP, and the first to report a dose-response variant of this adverse reaction.

show abstract

Section: Case Presentationmentioning

confidence: 89%

Lisinopril‐associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction

Ballout

Musharrafıeh

Khattar

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first observational study investigating the influence of ACE inhibitor and ARB use and incident RA. Evidence for the association between ACE inhibitor and/or ARB use and the occurrence of autoimmune diseases was derived from case reports of lupus‐like disease, vasculitis, and pemphigus . In these case reports, the commonly prescribed ACE inhibitors such as captopril and enalapril were often reported as a suspected drug for the occurrence of these autoimmune diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Otherwise, it has been postulated that the immunomodulating effects of ACE inhibitors may facilitate autoimmune responses . Indeed, several case reports have suggested that ACE inhibitors may facilitate the development of autoantibodies and autoimmune diseases such as lupus‐like syndrome, vasculitis, and pemphigus . Furthermore, one patient with ARB‐associated pemphigus has been reported …”

Section: Introductionmentioning

confidence: 99%

Angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users

Jong

Vandebriel

Saldi

et al. 2012

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…It was recently shown that pemphigus foliaceus might be induced by lisinopril. 6 To our knowledge, we are presenting the first patient in whom BP developed during treatment with lisinopril-another ACE inhibitor lacking the thiol group ( Fig. 1).…”

mentioning

confidence: 93%

“…These drugs are used for the treatment of arterial hypertension, either as a monotherapy or in combination with other drugs, and in congestive heart failure. It was recently shown that pemphigus foliaceus might be induced by lisinopril 6 . To our knowledge, we are presenting the first patient in whom BP developed during treatment with lisinopril—another ACE inhibitor lacking the thiol group (Fig.…”

mentioning

confidence: 97%

Can pemphigoid be provoked by lisinopril?

Kalińska-Bienias

Rogozinski

Woźniak

et al. 2006

British Journal of Dermatology

View full text Add to dashboard Cite

References1 Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-54. 2 Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-33. 3 Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFRtargeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-46. 4 Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-24. 5 van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601. 6 Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-76. 7 Suh KY, Kindler HL, Medenica M, Lacouture ME. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor cetuximab. Br J Dermatol 2006; 154:191-2. 8 Lacouture ME, Basti S, Patel J, Benson A III. The SERIES clinic: an interdisciplinary approach to the management of toxicities to EGFR inhibitors. J Support Oncol 2006; 4:236-39. 9 Murillas R, Larcher F, Conti CJ et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216-23. 10 Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209:123-9.Fig 2.Laser scanning confocal microscopic study on the patient's skin showed the presence of in vivo-bound linear IgG deposits along the basement membrane zone: (a) colocalized with b4 integrin (yellow staining due to overlapping of green fluorescence of IgG and red fluorescence of b4 integrin) and (b) localized above laminin 5 (red staining of laminin 5 below the green fluorescence of IgG). Scale bar ¼ 10 lm.

show abstract

Pemphigus foliaceus: an adverse reaction to lisinopril

Cited by 24 publications

References 8 publications

Lisinopril‐associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction

Lisinopril‐associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction

Angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users

Can pemphigoid be provoked by lisinopril?

Contact Info

Product

Resources

About